Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | CCKAR | P32238 | 1/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 6/20 | 0.37 |
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7160937 | 0.95 | IDO1 (0.43) | IDO1ITGB3ITGA2BACECCKAR | |
| SCHEMBL14181791 | 0.90 | IDO1 (0.40) | IDO1ACECCKARCCKBRPPARA | |
| SCHEMBL7167872 | 0.86 | IDO1 (0.46) | IDO1ITGB3ITGA2BACECCKAR | |
| SCHEMBL7160952 | 0.84 | ITGB3 (0.45) | IDO1ITGB3ITGA2BACECCKAR | |
| SCHEMBL7164960 | 0.84 | IDO1 (0.48) | IDO1ITGB3ITGA2BACECCKAR | |
| SCHEMBL7169163 | 0.84 | IDO1 (0.43) | IDO1ITGB3ITGA2BACECCKAR | |
| SCHEMBL7164986 | 0.84 | IDO1 (0.44) | IDO1ITGB3ITGA2BACECCKAR | |
| SCHEMBL6450695 | 0.82 | IDO1 (0.39) | IDO1ITGB3ITGA2BACECCKAR | |
| SCHEMBL7159936 | 0.82 | ITGB3 (0.43) | IDO1ITGB3ITGA2BACECCKAR | |
| SCHEMBL6570924 | 0.81 | USP2 (0.34) | USP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7648959-B2 | Methods and compositions for the treatment of diseases of the eye | MERCK PATENT GMBH (DE) | 2010-01-19 | — | — | US | claimed |
| US-7645736-B2 | injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid | MERCK PATENT GMBH (DE) | 2010-01-12 | — | — | US | claimed |
| US-20060287225-A1 | Integrin inhibitors for the treatment of eye diseases | SCRIPPS RESEARCH INSTITUTE, THE | 2006-12-21 | — | — | US | claimed |
| US-20060223746-A1 | Methods and compositions for the treatment of diseases of the eye | SCRIPPS RESEARCH INSTITUTE, THE | 2006-10-05 | — | — | US | claimed |
| EP-1411926-B1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2005-06-01 | — | — | EP | claimed |
| US-20050085415-A1 | Methods and compositions for the treatment of eye diseases | MERCK PATENT GMBH (DE) | 2005-04-21 | — | — | US | claimed |
| EP-1474162-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GmbH (DE) | 2004-11-10 | — | — | EP | claimed |
| US-20040198644-A1 | Integrin inhibitors for the treatment of eye diseases | MERCK PATENT GESELLSCHAFT (DE) | 2004-10-07 | — | — | US | claimed |
| EP-1411926-A1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GmbH (DE) | 2004-04-28 | — | — | EP | claimed |
| WO-2003068253-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2003-08-21 | — | — | WO | claimed |
| US-6559144-B2 | Integrin inhibitors used to treat circulatory disorders, for thrombosis, myocardial infarct, coronary heart disease, arteriosclerosis, osteoporosis, pathological processes maintained or propagated by angiogenesis and tumor therapy | MERCK PATENT GESELLSCHAFT MIT (DE) | 2003-05-06 | — | — | US | claimed |
| WO-2003013511-A1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2003-02-20 | — | — | WO | claimed |
| EP-0964856-B1 | BICYCLIC AMINO ACIDS | MERCK PATENT GMBH (DE) | 2002-10-09 | — | — | EP | claimed |
| US-20010021709-A1 | Bicyclic amino acids | MERCK PATENT GESELLSCHAFT MIT BESCHRANKT PATENTS (DE) | 2001-09-13 | — | — | US | claimed |
| US-7645736-B2 | injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid | MERCK PATENT GMBH (DE) | 2010-01-12 | — | — | US | disclosed |
| US-20060287225-A1 | Integrin inhibitors for the treatment of eye diseases | SCRIPPS RESEARCH INSTITUTE, THE | 2006-12-21 | — | — | US | disclosed |
| EP-1411926-B1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2005-06-01 | — | — | EP | disclosed |
| EP-1381382-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OF THE EYE | MERCK PATENT GmbH (DE) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003068253-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2003-08-21 | — | — | WO | disclosed |
| WO-2002041910-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OF THE EYE | MERCK PATENT GMBH (DE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198644-A1 | Integrin inhibitors for the treatment of eye diseases | ITGA5, ITGB5, ITGAV | IDO1 1538/4885ITGB3 5/4885ITGA2B 7/4885 |
| US-20010021709-A1 | Bicyclic amino acids | ITGA1, ITGB1, ITGB2 | IDO1 1398/4885ITGB3 5/4885ITGA2B 14/4885 |
| US-20060287225-A1 | Integrin inhibitors for the treatment of eye diseases | ITGA5, ITGAV, ITGB5 | IDO1 1384/4885ITGB3 4/4885ITGA2B 7/4885 |
| US-20060223746-A1 | Methods and compositions for the treatment of diseases of the eye | ITGA5, ITGAV, ITGB5 | IDO1 4250/4885ITGB3 4/4885ITGA2B 6/4885 |
| US-20050085415-A1 | Methods and compositions for the treatment of eye diseases | ITGA5, ITGB5, ITGAV | IDO1 1288/4885ITGB3 4/4885ITGA2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.